Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4879-4884

  Davis, Stephanie L ^a   Nuermberger, Eric L ^a   Um, Peter K ^a   Vidal, Camille ^b,c   Jedynak, Bruno ^c   Pomper, Martin G ^a   Bishai, William R ^a   Jain, Sanjay K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University   (United States)

^c Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; FLUORODEOXYGLUCOSE F 18; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; COLONY FORMING UNIT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG MONITORING; FEMALE; HISTOPATHOLOGY; LUNG GRANULOMA; LUNG LESION; LUNG TUBERCULOSIS; MICROBIOLOGICAL EXAMINATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NON INVASIVE PROCEDURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT RESPONSE; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; GRANULOMA; LUNG; METABOLISM; SCINTISCANNING;

ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; GRANULOMA; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECURRENCE; TUBERCULOSIS;

EID: 70350322939     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00789-09     Document Type: Article

References (32)

1. Alavi, A., N. Gupta, J. L. Alberini, M. Hickeson, L. E. Adam, P. Bhargava, and H. Zhuang. 2002. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin. Nucl. Med. 32:293-321.
2. Aung, H., Z. Toossi, J. J. Wisnieski, R. S. Wallis, L. A. Culp, N. B. Phillips, M. Phillips, L. E. Averill, T. M. Daniel, and J. J. Ellner. 1996. Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of Mycobacterium tuberculosis and synergism with fibronectin. J. Clin. Investig. 98:1261-1268.
3. Bekker, L. G., G. Maartens, L. Steyn, and G. Kaplan. 1998. Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J. Infect. Dis. 178:580-584.
4. Bell, G. I., C. F. Burant, J. Takeda, and G. W. Gould. 1993. Structure and function of mammalian facilitative sugar transporters. J. Biol. Chem. 268:19161-19164.
5. Bettegowda, C., C. A. Foss, I. Cheong, Y. Wang, L. Diaz, N. Agrawal, J. Fox, J. Dick, L. H. Dang, S. Zhou, K. W. Kinzler, B. Vogelstein, and M. G. Pomper. 2005. Imaging bacterial infections with radiolabeled 1-(2′-deoxy-2′-fluoro-beta-D-arabinofuranosyl)-5-iodouracil. Proc. Natl. Acad. Sci. USA 102:1145-1150.
6. CDC. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55:301-305.
7. Davis, S., P. Um, G. Lamichhane, S. Nimmagadda, M. G. Pomper, W. R. Bishai, and S. K. Jain. 2008. Monitoring disease in animal models of TB: the 21st century: non-invasive, real-time, in live animals, abstr. B-874. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother./46th Infect. Dis. Soc. Am. Annu. Meet., Washington, DC, October 2008.
8. Davis, S. L., N. B. Be, G. Lamichhane, S. Nimmagadda, M. G. Pomper, W. R. Bishai, and S. K. Jain. 2009. Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS ONE 4:e6297.
9. Davis, S. L., P. Um, G. Lamichane, S. Nimmagadda, M. G. Pomper, W. R. Bishai, and S. K. Jain. 2009. Keystone Symposia on Tuberculosis: Biology, Pathology, and Therapy (B3), abstr. 178. Keystone, CO, 25 to 30 January 2009.
10. Davis, S. L., P. Um, G. Lamichane, S. Nimmagadda, M. G. Pomper, W. R. Bishai, and S. K. Jain. 2008. Abstr. World Mol. Imaging Congr., abstr. 294. Nice, France, 10 to 13 September 2008.
11. Demura, Y., T. Tsuchida, D. Uesaka, Y. Umeda, M. Morikawa, S. Ameshima, T. Ishizaki, Y. Fujibayashi, and H. Okazawa. 2009. Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur. J. Nucl. Med. Mol. Imaging 36:632-639.
12. Flynn, J. L. 2006. Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect. 8:1179-1188.
13. Goo, J. M., J. G. Im, K. H. Do, J. S. Yeo, J. B. Seo, H. Y. Kim, and J. K. Chung. 2000. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 216:117-121.
14. Hutchens, M., and G. D. Luker. 2007. Applications of bioluminescence imaging to the study of infectious diseases. Cell. Microbiol. 9:2315-2322.
15. Jain, S. K., P. Kwon, and W. J. Moss. 2005. Management and outcomes of intracranial tuberculomas developing during antituberculous therapy: case report and review. Clin. Pediatr. (Philadelphia) 44:443-450.
16. Jain, S. K., G. Lamichhane, S. Nimmagadda, M. G. Pomper, and W. R. Bishai. 2008. Antibiotic treatment of tuberculosis: old problems, new solutions. Microbe 3:285-292.
17. Kubota, R., S. Yamada, K. Kubota, K. Ishiwata, N. Tamahashi, and T. Ido. 1992. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med. 33:1972-1980.
18. Mdivani, N., H. Li, M. Akhalaia, M. Gegia, L. Goginashvili, D. S. Kernodle, G. Khechinashvili, and Y. W. Tang. 2009. Monitoring therapeutic efficacy by real-time detection of Mycobacterium tuberculosis mRNA in sputum. Clin. Chem. 55:1694-1700.
19. Mochizuki, T., E. Tsukamoto, Y. Kuge, K. Kanegae, S. Zhao, K. Hikosaka, M. Hosokawa, M. Kohanawa, and N. Tamaki. 2001. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J. Nucl. Med. 42:1551-1555.
20. Paik, J. Y., K. H. Lee, Y. S. Choe, Y. Choi, and B. T. Kim. 2004. Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J. Nucl. Med. 45:124-128.
21. Pan, H., B. S. Yan, M. Rojas, Y. V. Shebzukhov, H. Zhou, L. Kobzik, D. E. Higgins, M. J. Daly, B. R. Bloom, and I. Kramnik. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434:767-772. (Pubitemid 44739520)
22. Park, I. N., J. S. Ryu, and T. S. Shim. 2008. Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography. Clin. Nucl. Med. 33:1-3.
23. Pauwels, E. K., M. J. Ribeiro, J. H. Stoot, V. R. McCready, M. Bourguignon, and B. Maziere. 1998. FDG accumulation and tumor biology. Nucl. Med. Biol. 25:317-322.
24. Perrin, F. M., M. C. Lipman, T. D. McHugh, and S. H. Gillespie. 2007. Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect. Dis. 7:481-490.
25. 18F]-labeled 2′-deoxycytidine analog. Nat. Med. 14:783-788.
26. Rook, G. A., J. Taverne, C. Leveton, and J. Steele. 1987. The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 62:229-234.
27. Rosenthal, I. M., K. Williams, S. Tyagi, A. A. Vernon, C. A. Peloquin, W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2005. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 172:1457-1462.
28. Rosenthal, I. M., M. Zhang, K. N. Williams, C. A. Peloquin, S. Tyagi, A. A. Vernon, W. R. Bishai, R. E. Chaisson, J. H. Grosset, and E. L. Nuermberger. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344.
29. Schluger, N. W. 2007. Keystone Symposia on Tuberculosis: from Lab Research to Field Trials (C6), abstr. 041, Vancouver, British Columbia, Canada, 20 to 25 March 2007.
30. Vidal, C., J. Hewitt, S. Davis, L. Younes, S. Jain, and B. Jedynak. 2009. Template registration with missing parts: application to the segmentation of tuberculosis infected lungs, p. 718-721. Proceedings of the IEEE International Symposium on Biomedical Imaging, Boston, MA.
31. Yanardag, H., C. Tetikkurt, S. Tetikkurt, S. Demirci, and T. Karayel. 2003. Computed tomography and bronchoscopy in endobronchial tuberculosis. Can. Respir. J. 10:445-448.
32. Zhuang, H., and A. Alavi. 2002. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin. Nucl. Med. 32:47-59.